New clinical data show sustained correction of HIV‑associated facial lipoatrophy using Teoxane’s RHA® dermal fillers

New real world clinical data presented at AMWC 2026 demonstrate that Teoxane’s Resilient Hyaluronic Acid (RHA®) dermal fillers, manufactured with Preserved Network Technology (PNT), provide effective, durable, and well tolerated correction of facial lipoatrophy (FLA) in people living with HIV.

The study followed 29 patients with moderate to severe facial volume loss and demonstrated consistent improvements across blinded evaluator assessments, patient satisfaction, and 3D volumetric analysis over 24 months.

Facial lipoatrophy (FLA) remains one of the most visible and psychologically impactful consequences of long-term antiretroviral treatment and is increasingly observed with the broader use of certain antidiabetic and obesity medications. The findings support the use of RHA® fillers as a reliable, minimally invasive approach to restoring facial harmony in these medically driven conditions.

This investigator led, non-comparative study explored the performance and safety of the RHA® range across key facial zones affected by FLA, including the cheeks, temples, infraorbital region and perioral areas. Injectors selected among the different RHA® products according to rheology, depth, and treatment objectives.

Patients were followed for 24 months, with optional touch ups at months 1, 2 and 6. Efficacy was assessed by a blinded evaluator using a validated 4 grade FLA scale, complemented by GAIS scores, patient and investigator satisfaction, DLQI outcomes, and exploratory 3D volumetric analysis.

Clinically meaningful volume restoration

•    The primary endpoint was met, with 27 (93.1%) subjects achieving ≥ 1-grade improvement at month 6, with mean change in FLA score from baseline to month 6 was -1.4 ± 0.7 (p<0.001).  

•    Improvements remained high through 24 months, with ≥86.4% of patients maintaining at least a 1 grade improvement.

High and sustained satisfaction levels

•    Patient satisfaction exceeded 82% at all visits, peaking at 95.7% at month 24.

•    Individual DLQI results showed reduction in daily life impact up to 12 months  

Objective 3D volumetric confirmation

•    Canfield VECTRA® analysis confirmed visible, quantifiable soft tissue gains in the midface and nasolabial fold regions, with increases maintained up to 24 months.

•    3D imagery showed sustained anatomical improvements following combination treatments and touch ups.

Favorable safety profile

No serious adverse events related to the device or procedure were reported throughout the 24‑month study.

These findings reported in the AMWC conference poster support the use of Teoxane’s RHA® range as a reproducible and effective approach for restoring facial volume in people living with HIV, with sustained outcomes, high patient satisfaction, and and a favorable safety profile. They also contribute to the emerging rationale for applying RHA® technology in other medically driven facial volume loss conditions.

Reference

Negulescu V, Trevidic P, Poupard K. Non-surgical correction of facial lipoatrophy in people living with HIV using a range of commercially available injectable cross-linked hyaluronic acid dermal fillers: A prospective, singleblind study. Poster presented at AMWC 2026; Monaco.